These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25998051)

  • 21. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AXL kinase as a novel target for cancer therapy.
    Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
    Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric aptamers in cancer cell-targeted drug delivery.
    Kanwar JR; Roy K; Kanwar RK
    Crit Rev Biochem Mol Biol; 2011 Dec; 46(6):459-77. PubMed ID: 21955150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.
    Paccez JD; Vogelsang M; Parker MI; Zerbini LF
    Int J Cancer; 2014 Mar; 134(5):1024-33. PubMed ID: 23649974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging.
    Zhong J; Ding J; Deng L; Xiang Y; Liu D; Zhang Y; Chen X; Yang Q
    Drug Des Devel Ther; 2021; 15():3985-3996. PubMed ID: 34584404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axl inhibitors as novel cancer therapeutic agents.
    Shen Y; Chen X; He J; Liao D; Zu X
    Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aptamer-MiRNA Conjugates for Cancer Cell-Targeted Delivery.
    Esposito CL; Catuogno S; de Franciscis V
    Methods Mol Biol; 2016; 1364():197-208. PubMed ID: 26472452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.
    Esposito CL; Passaro D; Longobardo I; Condorelli G; Marotta P; Affuso A; de Franciscis V; Cerchia L
    PLoS One; 2011; 6(9):e24071. PubMed ID: 21915281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
    Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
    Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Xu F; Li H; Sun Y
    Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
    Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.
    Gilboa-Geffen A; Hamar P; Le MT; Wheeler LA; Trifonova R; Petrocca F; Wittrup A; Lieberman J
    Mol Cancer Ther; 2015 Oct; 14(10):2279-91. PubMed ID: 26264278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma.
    Flem-Karlsen K; McFadden E; Omar N; Haugen MH; Øy GF; Ryder T; Gullestad HP; Hermann R; Mælandsmo GM; Flørenes VA
    Mol Cancer Ther; 2020 Mar; 19(3):895-905. PubMed ID: 31871265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted delivery system using silica nanoparticles coated with chitosan and AS1411 for combination therapy of doxorubicin and antimiR-21.
    Khatami F; Matin MM; Danesh NM; Bahrami AR; Abnous K; Taghdisi SM
    Carbohydr Polym; 2021 Aug; 266():118111. PubMed ID: 34044928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
    Liang X; Wang Y; Shi H; Dong M; Han H; Li Q
    Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
    Boshuizen J; Pencheva N; Krijgsman O; Altimari DD; Castro PG; de Bruijn B; Ligtenberg MA; Gresnigt-Van den Heuvel E; Vredevoogd DW; Song JY; Visser N; Apriamashvili G; Janmaat ML; Plantinga TS; Franken P; Houtkamp M; Lingnau A; Jure-Kunkel M; Peeper DS
    Cancer Res; 2021 Apr; 81(7):1775-1787. PubMed ID: 33531370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.